Artificial intelligence models for diagnosing post-traumatic stress disorder

San­doz said Tues­day that the FDA signed off on two of its biosim­i­lars to Am­gen’s bone drug deno­sum­ab. But as with oth­er high-pro­file biosim­i­lar ap­provals,

The un­met need for pa­tients with the pro­gres­sive neu­rode­gen­er­a­tive dis­ease ALS, or amy­otroph­ic lat­er­al scle­ro­sis, is un­doubt­ed­ly high. But the FDA is draw­ing the line